Analyst Activity – Raymond James Financial, Inc. Initiates Coverage On Cidara Therapeutics (NASDAQ:CDTX) With a Strong-Buy

8

Analyst Ratings For Cidara Therapeutics (NASDAQ:CDTX)

Today, Raymond James Financial, Inc. initiated coverage on Cidara Therapeutics (NASDAQ:CDTX) with a Strong-Buy.

There are 1 hold rating, 8 buy ratings, 1 strong buy rating on the stock.

The current consensus rating on Cidara Therapeutics (NASDAQ:CDTX) is Buy (Score: 3.00) with a consensus target price of $13.39 per share, a potential 112.52% upside.

Some recent analyst ratings include

  • 4/20/2017-Raymond James Financial, Inc. initiated coverage with a Strong-Buy rating.
  • 4/17/2017-HC Wainwright Reiterated Rating of Buy .
  • 4/12/2017-Ladenburg Thalmann Financial Services initiated coverage with a Buy rating.
  • 4/10/2017-Wedbush Reiterated Rating of Outperform .
  • 4/10/2017-Needham & Company LLC Reiterated Rating of Buy.
  • 4/7/2017-Cantor Fitzgerald Reiterated Rating of Buy.
  • 3/24/2017-Jefferies Group LLC Reiterated Rating of Buy.

Dividend information for Cidara Therapeutics (NASDAQ:CDTX)

.
Recent Insider Trading Activity For Cidara Therapeutics (NASDAQ:CDTX)
Cidara Therapeutics (NASDAQ:CDTX) has insider ownership of 22.20% and institutional ownership of 47.34%.

  • On 3/31/2017 Jeffrey Stein, CEO, bought 12,900 with an average share price of $7.75 per share and the total transaction amounting to $99,975.00. View SEC Filing
  • On 3/31/2017 Kevin Forrest, Insider, bought 12,500 with an average share price of $7.75 per share and the total transaction amounting to $96,875.00. View SEC Filing
  • On 5/20/2016 Jeffrey Stein, CEO, bought 4,310 with an average share price of $11.51 per share and the total transaction amounting to $49,608.10. View SEC Filing
  • On 5/20/2016 Kevin Forrest, CFO, bought 4,356 with an average share price of $11.53 per share and the total transaction amounting to $50,224.68. View SEC Filing
  • On 11/25/2015 Jeffrey Stein, CEO, bought 6,700 with an average share price of $15.09 per share and the total transaction amounting to $101,103.00. View SEC Filing
  • On 11/23/2015 Kevin Forrest, CFO, bought 7,087 with an average share price of $14.23 per share and the total transaction amounting to $100,848.01. View SEC Filing
  • On 4/20/2015 Timothy R Franson, Director, bought 4,000 with an average share price of $16.00 per share and the total transaction amounting to $64,000.00. View SEC Filing

About Cidara Therapeutics (NASDAQ:CDTX)
Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. The Company is also developing CD201, its bispecific antimicrobial immunotherapy.

Recent Trading Activity for Cidara Therapeutics (NASDAQ:CDTX)
Shares of Cidara Therapeutics closed the previous trading session at 6.30 down -0.05 -0.79% with 82,300 shares trading hands.

An ad to help with our costs